Modality
Radioligand
MOA
BCMA ADC
Target
KRASG12D
Pathway
Tau
NMOSDHeart Failure
Development Pipeline
Preclinical
~Apr 2012
→ ~Jul 2013
Phase 1
~Oct 2013
→ ~Jan 2015
Phase 2
~Apr 2015
→ ~Jul 2016
Phase 3
~Oct 2016
→ ~Jan 2018
NDA/BLA
Apr 2018
→ May 2026
NDA/BLACurrent
NCT06062256
1,750 pts·Heart Failure
2018-04→2026-05·Completed
NCT03132988
308 pts·Heart Failure
2021-01→TBD·Terminated
2,058 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-05-111mo awayPh3 Readout· Heart Failure
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Complet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-05-11 · 1mo away
Heart Failure
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06062256 | NDA/BLA | Heart Failure | Completed | 1750 | Mayo |
| NCT03132988 | NDA/BLA | Heart Failure | Terminated | 308 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |